New findings about why losartan is effective in treating Marfan syndrome may reshape our thinking

February 9, 2018, Elsevier

Progressive dilation of the aortic root is considered one of the most serious manifestations of Marfan syndrome because it can lead to aortic dissection and death. Pharmacotherapy is used to attenuate the progression of this aortic enlargement. The antihypertensive losartan is one of the two medications recommended by current guidelines, but which medication works best is still controversial. A new report in the American Journal of Pathology confirms losartan's efficacy but finds that the underlying mechanism of action is different than previously thought, opening up new possibilities for improvements in Marfan syndrome management.

Losartan, a common blood-pressure lowering medication, is routinely used prophylactically by Marfan patients to help prevent or delay aortic root disease. "Our team has identified a possible new direction for the management of Marfan patients. Contrary to most preconceptions, reducing blood pressure and heart rate does not attenuate aortic root widening in Marfan mice. Instead, activation of and protective endothelial nitric oxide release appear to be key to losartan's anti-aortic root remodeling activities. This was completely unexpected," explained Pascal-Nicolas Bernatchez, PhD, of the Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, Vancouver. "From a patient outcome perspective, our data support the concept that focusing on blood pressure lowering and cardiac hemodynamics in Marfan syndrome might be of low therapeutic value, whereas focusing on gains in endothelial function might be preferable."

Losartan is recommended for Marfan patients due to its unique anti-remodeling properties, which other antihypertensive agents, such as angiotensin converting enzyme inhibitors (ACEi), lack. (Vascular remodeling refers to changes in the structure of blood vessels, such as increased wall thickness or lumen diameter.) In Marfan syndrome the pathological changes in the aortic root are thought to be related to angiotensin II receptor 1 (ART1) signaling and the anti-remodelling effects of losartan mediated by blocking ART1 signaling and downstream transforming growth factor-beta. The current study proposes a more complex view of this pathway.

In collaboration with Investigators from the British Columbia Children's Hospital Research Institute, the team used genetically altered mice that display many of the features of Marfan syndrome and bred them with hypotensive and bradycardic mice with blunted ATR1 expression. To their surprise, the progeny developed aortic root disease aggressively and remained fully responsive to losartan, indicating a possible "off target" effect that results in increased anti-remodelling nitric oxide release.

"This could explain why losartan is considered a wonder drug, since it has the unique ability to activate protective endothelial function in disease settings, something aerobic exercise is also known to do. Therefore, we may have documented a novel way to activate endothelial function in a therapeutically-meaningful manner and characterized differences between regulation and nitric oxide-dependent endothelial function, noted Dr. Bernatchez.

The investigators propose that other antihypertensive agents do not share losartan's ability to activate endothelial function and may explain why they are not beneficial for Marfan syndrome. Titrating the dose of losartan according to the effect on endothelial function may optimize treatment in the future, whereas new therapies may be developed to focus on the anti-remodelling properties of endothelial function.

"Our findings stress the importance of activating protective endothelial function and nitric oxide release during treatment, a concept supported by the work of other member of our research group. Endothelial activation could be the basis for improved Marfan patient management," commented Dr. Bernatchez.

Marfan syndrome is an autosomal dominant connective tissue disorder that occurs in 1 in 5,000 to 10,000 individuals. Affected individuals have mutations in the fibrillin 1 gene and these interfere with the proper formation and stabilization of elastic fibers in the walls of blood vessels and other tissues. The most serious manifestation of Marfan syndrome is progressive aortic root dilation with increased risk of mitral valve prolapse and aortic aneurysm. Other problems may arise in the lungs, eyes, bones, and covering of the spinal cord. Individuals diagnosed with Marfan are often tall and thin, with long arms, legs, fingers, and toes.

Explore further: Common blood pressure drug reduces aortic enlargement in Marfan syndrome

More information: "Inhibition of Marfan Syndrome Aortic Root Dilation by Losartan: Role of ATR1-Independent Activation of Endothelial Function," American Journal of Pathology (2018). DOI: 10.1016/j.ajpath.2017.11.006

Related Stories

Common blood pressure drug reduces aortic enlargement in Marfan syndrome

September 2, 2013
A common drug that is used to treat high blood pressure in the general population has been found to significantly reduce a dangerous and frequently fatal cardiac problem in patients with Marfan syndrome.

Researchers reverse heart failure in Marfan mice

November 14, 2017
In experiments with mice that have a rodent form of Marfan syndrome, Johns Hopkins researchers report that even modestly increasing stress on the animals' hearts—at levels well-tolerated in normal mice—can initiate heart ...

Moderate exercise training improves some of the Marfan syndrome symptoms in mice

December 18, 2017
Regular physical activity is a common therapy for people with cardiovascular problems, but not recommended to those with Marfan syndrome, a rare disease of the connective tissue affecting the cardiovascular system. A study ...

New treatment for Marfan syndrome shows promise

November 18, 2014
An investigational treatment for Marfan syndrome is as effective as the standard therapy at slowing enlargement of the aorta, the large artery of the heart that delivers blood to the body, new research shows. The findings ...

Recommended for you

Omega 3 supplements have little or no heart or vascular health benefit: review

July 17, 2018
New evidence published today shows there is little or no effect of omega 3 supplements on our risk of experiencing heart disease, stroke or death.

Researchers discover new genes associated with heart function

July 17, 2018
A new study from an international research team, led by Dr. Yalda Jamshidi at St George's, University of London, has identified new genes associated with heart function and development.

Southern diet could be deadly for people with heart disease

July 12, 2018
People with a history of heart disease who eat a traditional Southern diet are more likely to die than those who follow a Mediterranean dietary pattern, according to new research.

Late-life high blood pressure may harm the brain, study says

July 11, 2018
Decades ago, hundreds of nuns and priests made an extraordinary decision: They agreed to donate their brains upon death to science, hoping to help solve mysteries about Alzheimer's and other diseases. Now, a study that used ...

Multivitamins do not promote cardiovascular health

July 10, 2018
Taking multivitamin and mineral supplements does not prevent heart attacks, strokes or cardiovascular death, according to a new analysis of 18 studies published in Circulation: Cardiovascular Quality and Outcomes, an American ...

Mobile health devices diagnose hidden heart condition in at-risk populations

July 10, 2018
Wearable mobile health devices improved the rate of diagnosis of a dangerous and often hidden heart condition called atrial fibrillation (AFib), according to a first of its kind, home-based clinical study conducted in part ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

Anonym675367
not rated yet Feb 09, 2018
I was beginning to have high blood pressure issues on May 18th, 2017. When my doctor increased my meds a second time, I decided to take things seriously. With a heart attack, I would either die, or not. But a stroke would be a whole different story I wanted to avoid. It was my good fortune I found Mary's blood pressure treatment story (google " How I Helped My Sister Cure Hypertension " ). It is a quick read and gives very simple explanations for what is needed to drop your BP. I am amazed at how easy it was to do the program and how quickly I got results. In just two weeks I got my BP to slightly below normal and even lost a few pounds. In a follow-up visit my doctor reduced my meds and when I report the latest data, she will probably reduce my meds even further. The truth is we can get off the drugs and help myself by trying natural methods

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.